Why do patients with atrial fibrillation not receive warfarin?

Archives of Internal Medicine

Volumn 160, Issue 1, 2000, Pages 41-46

  Bungard, Tammy J ^a   Ghali, William A ^b   Teo, Koon K ^a   McAlister, Finlay A ^c   Tsuyuki, Ross T ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ALBERTA ENVIRONMENT AND PARKS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; HEALTH CARE SYSTEM; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT INDICATION;

EID: 0034627893     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.1.41     Document Type: Review

References (54)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469-473.
2. Albers GW, Atwood JE, Hirsh J, Sherman DG, Hughes RA, Connolly SJ. Stroke prevention in non-valvular atrial fibrillation. Ann Intern Med. 1991; 115:727-736.
3. Cerebral Embolism Task Force. Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force. Arch Neurol. 1989;46:727-743.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987; 147:1561-1564.
6. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349-351.
7. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
8. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-1412.
9. Petersen P, Boysen G, Godfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;177:175-179.
10. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84:527-539.
11. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med. 1990; 323:1505-1511.
12. Albers GW, Bittar N, Young L, et al. Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology. 1997;48:1598-1604.
13. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med. 1996; 11:713-720.
14. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ. 1993;307:1045.
15. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients witn nonrheumatic atrial fibrillation? J Gen Intern Med. 1996; 11:721-728.
16. Brass LM, Krurnholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997;28:2382-2389.
17. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154:1945-1953.
18. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978-984.
19. Hendry A, Campbell AM, Campbell G, Macdonald JB, Williams BO. Antithrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation. Scott Med J. 1994;39:110-111.
20. Lip GYH, Golding D, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997;47:285-289.
21. Lip GY, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994;71:92-95.
22. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke. 1997;28:72-76.
23. O'Connell JE, Gray CS. Atrial fibrillation and stroke prevention in the community. Age Aging. 1996; 25:307-309.
24. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996; 156:2537-2541.
25. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998;352:1167-1171.
26. The Clinical Quality Improvement Network (COIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol. 1998;14:695-702.
27. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med. 1997;157: 441-445.
28. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med. 1996;156:2553-2562.
29. Chang HJ, Bell JR, Devoo DB, Kirk JW, Wasson JH. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990; 150:81-84.
30. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991; 151:1950-1953.
31. Lip GYH, Zarifis J, Watson RDS, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart. 1996;75:200-205.
32. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
33. Monette J, GurwitzJH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45:1060-1065.
34. Rodgers H, Sudlow M, Dobson R, Kenny RA, Thomson RG. Warfarin anticoagulation in primary care: a regional survey of present practice and clinicians' views. Br J Gen Pract. 1997;47: 309-310.
35. Tsuyuki RT, Walters B, Yim R, Teo KK. Temporal changes in thromboembolic prophylaxis in atrial fibrillation [letter]. Can J Cardiol. In press.
36. Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-1848.
37. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke. 1998;29:1827-1832.
38. Lawson F, McAlister F, Ackman M, Ikuta R, Montague T. The utilization of antithrombotic prophylaxis for atrial fibrillation. J Am Geriatr Soc. 1996; 44:1-4.
39. Howard PA, Duncan PW. Primary stroke prevention in non-valvular atrial fibrillation: implementing the clinical trial findings. Ann Pharmacother. 1997;31:1187-1196.
40. Edwards A, Pill R. Quality of service provision for anticoagulation in atrial fibrillation: bridges from evidence to practice are fragile [letter]. BMJ. 1996; 312:51.
41. Thomson R, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ. 1998;316:509-513.
42. Lip GY. Quality of service provision for anticoagulation in atrial fibrillation: many patients are ineligible [letter]. BMJ. 1996;312:51.
43. Sudlow CM, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ. 1995;311:558-561.
44. Taylor F, Ramsay M, Voke J. Cohen H. Anticoagulation in patients with atrial fibrillation: GPs not prepared for monitoring anticoagulation [letter]. BMJ. 1993;307:1493.
45. Scott ME, Wallace WF. Quality of service provision for anticoagulation in atrial fibrillation: patients and doctors play it safe. BMJ. 1996;312: 51-52.
46. Hartley RM, Charlton JR, Jarman B, Harris CM. Case history questionnaires in the study of doctors' use of resources: are they measuring what we want? Med Care. 1985;23:1163-1170.
47. Jones TV, Gerrity MS, Earp J. Written case simulations: do they predict physicians' behavior? J Clin Epidemiol. 1990;43:805-815.
48. Kemeny ME, Hargreaves WA, Gerbert B, Sone GC, Gullion DS. Measuring adequacy of physician performance: a preliminary comparison of four methods in ambulatory care of chronic obstructive pulmonary disease. Med Care. 1984;22:620-631.
49. Morrell DC, Roland MO. Analysis of referral behaviour: responses to simulated case histories may not reflect real clinical behaviour. Br J Gen Pract. 1990;40:182-185.
50. Page GG, Fielding DW. Performance on PMPs and performance in practice: are they related? J Med Educ. 1980;55:529-537.
51. Rethans JJ, Sturmans F, Drop R, van der Vleuten C, Hobus P. Does competence of general practitioners predict their performance? comparison between examination setting and actual practice. BMJ. 1991;303:1377-1380.
52. Sandvik H. Criterion validity of responses to patient vignettes: an analysis based on management of female urinary incontinence. Fam Med. 1995;27:388-392.
53. Vu NM. Medical problem-solving assessment. Eval Health Prof. 1979;2:281-307.
54. Davis DA, Thomson MA, Oxman AD, Haynes B. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA. 1995;274:700-705.